Clinical Trial

The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy

Recruiting
View on ClinicalTrials.gov →
Summary
The objective of the study is to evaluate the predictive value of TMPRSS2-ERG gene fusion and PTEN in patients with high risk prostate cancer treated with first line LHRH agonist after biochemical failure.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2015-10-09; most recent amendment 2024-12-02.
Status change: Not Yet Recruiting → Recruiting 2016-04-12
Trial Details
NCT Number NCT02573636
Lead Sponsor Sir Mortimer B. Davis - Jewish General Hospital
Conditions Prostate Cancer
Enrollment 208 participants
Start Date 2016-03
Primary Completion 2026-11 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2024-12-04